These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 14962580)
81. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. Paulekuhn GS; Dressman JB; Saal C J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022 [TBL] [Abstract][Full Text] [Related]
82. A stepwise approach to evaluating new drug therapy. Wessell A; Blair M JAAPA; 2001 Nov; 14(11):10-1. PubMed ID: 11766421 [No Abstract] [Full Text] [Related]
83. Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods. Zacharis CK; Tzanavaras PD J Pharm Biomed Anal; 2008 Nov; 48(3):483-96. PubMed ID: 18599247 [TBL] [Abstract][Full Text] [Related]
84. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. Falit BP Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220 [No Abstract] [Full Text] [Related]
85. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk. Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527 [No Abstract] [Full Text] [Related]
87. Success rates for new drugs entering clinical testing in the United States. DiMasi JA Clin Pharmacol Ther; 1995 Jul; 58(1):1-14. PubMed ID: 7628176 [No Abstract] [Full Text] [Related]
89. Science meets beauty: using medicine to improve appearances. Rados C FDA Consum; 2004; 38(2):30-5. PubMed ID: 15101363 [No Abstract] [Full Text] [Related]
90. Pharmacogenomics: an in-house advantage? Borchardt PE Drug Discov Today; 2006 Jan; 11(1-2):1-3. PubMed ID: 16478684 [No Abstract] [Full Text] [Related]
91. Drug purchasing. Mehl B Hosp Pharm; 1988 Mar; 23(3):283-6. PubMed ID: 10318047 [No Abstract] [Full Text] [Related]
92. Is the drought over for pharming? Kaiser J Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771 [No Abstract] [Full Text] [Related]
93. Polymorph selection: the role of nucleation, crystal growth and molecular modeling. Erdemir D; Lee AY; Myerson AS Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526 [TBL] [Abstract][Full Text] [Related]
94. Determining drug equality. Hecht A FDA Consum; 1975 Nov; 9(9):18-20. PubMed ID: 10316633 [No Abstract] [Full Text] [Related]
95. New vaccine will help ease shortages. Child Health Alert; 2002 Jun; 20():3. PubMed ID: 12096724 [No Abstract] [Full Text] [Related]
96. Will compounding exist in the 21st century? Lynn RC J Am Vet Med Assoc; 1994 Jul; 205(2):296-7. PubMed ID: 7928606 [No Abstract] [Full Text] [Related]
97. Challenges of pediatric formulations: a FDA science perspective. Gupta A; Khan MA Int J Pharm; 2013 Nov; 457(1):346-8. PubMed ID: 24216242 [No Abstract] [Full Text] [Related]
98. Drug pipeline: Q311. Peng W Nat Biotechnol; 2011 Oct; 29(10):859. PubMed ID: 21997619 [No Abstract] [Full Text] [Related]
99. The Food and Drug Administration's drug approval process. Ahart GJ Conn Med; 1980 Mar; 44(3):161-6. PubMed ID: 7363619 [No Abstract] [Full Text] [Related]
100. A physicians's viewpoint. The Food and Drug Administration. Minno AM Pa Med; 1972 Jul; 75(7):61-2. PubMed ID: 5067716 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]